To include your compound in the COVID-19 Resource Center, submit it here.

ATX-MS-1467: Completed Phase IIa enrollment

Merck completed enrollment in an open-label, German Phase IIa trial evaluating ATX-MS-1467 for 20 weeks. Patients’ ATX-MS-1467

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE